Respiratory therapy

Encore Healthcare Announces Staggering Results in New Nexus TeleRespiratory Care Pilot Using Data to Predict when Oxygen/Nebulizer Patients Need Non-Invasive Ventilation (NIV) Before Hospitalizations Happen

Friday, June 11, 2021 - 1:32pm

LIVINGSTON, Tenn., June 11, 2021 /PRNewswire/ --Encore Healthcare announces staggering results from their new oxygen and nebulizer management Nexus TeleRespiratory Care model.

Key Points: 
  • LIVINGSTON, Tenn., June 11, 2021 /PRNewswire/ --Encore Healthcare announces staggering results from their new oxygen and nebulizer management Nexus TeleRespiratory Care model.
  • In the initial pilot with a national HME provider Encore identified 12.5% of patients on oxygen/nebulizers needed additional services including medications, NIV and High Frequency Chest Wall Oscillation (HFCWO).
  • These results are an example of how data can drive better patient outcomes and revenue to HME providers at the same time.
  • The Nexus platform aligns HME respiratory providers across traditional boundaries while increasing provider productivity and clinical outcomes with their Ventilator/High-Risk COPD patients.

Global Asthma and COPD Devices Market 2021-2026: Transforming Healthcare Infrastructure in Emerging Markets - ResearchAndMarkets.com

Friday, June 11, 2021 - 11:33am

The "Asthma and COPD Devices Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Asthma and COPD Devices Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2026" report has been added to ResearchAndMarkets.com's offering.
  • The report predicts the global asthma and COPD devices market to grow with a CAGR of 4.7% over the forecast period from 2020-2026.
  • Comprehensive analysis of the global as well as regional markets of the asthma and COPD devices market.
  • Complete coverage of all the segments in the asthma and COPD devices market to analyze the trends, developments in the global market and forecast of market size up to 2026.

Rapid Therapeutic Finalizes Lab Work on Pharmaceutical Formulas

Thursday, June 10, 2021 - 12:00pm

RTSL has developed three (3) proprietary pharmaceutical formulas, two (2) for cannabidiol (CBD) and one (1) for cannabigerol (CBG), to initially be used in Metered Dose Inhalers (MDI).

Key Points: 
  • RTSL has developed three (3) proprietary pharmaceutical formulas, two (2) for cannabidiol (CBD) and one (1) for cannabigerol (CBG), to initially be used in Metered Dose Inhalers (MDI).
  • RTSLs CEO, Donal R. Schmidt, Jr. stated, We initially set out to find an ultra-pure, unadulterated pharmaceutical grade CBD isolate to use in our MDI.
  • We also learned CBD isolate is not chemically compatible with metered dose inhalers without significant modifications in the manufacturing process.
  • In short, we were unsatisfied with any product we could source in the hemp space to meet our needs.

Verona Pharma and Nuance Pharma Announce $219 Million Strategic Collaboration to Develop and Commercialize Ensifentrine in Greater China

Thursday, June 10, 2021 - 7:00am

Ensifentrine also activates the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), which is beneficial in reducing mucous viscosity and improving mucociliary clearance.

Key Points: 
  • Ensifentrine also activates the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), which is beneficial in reducing mucous viscosity and improving mucociliary clearance.
  • Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs.
  • The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE (Ensifentrine as a Novel inHAled Nebulized COPD thErapy) for COPD maintenance treatment.
  • Since its inception in 2014, Nuance Pharma has assembled a portfolio of promising clinical-stage drug candidates for respiratory, pain and iron deficiency anemia.

Vapotherm to Host First Investor Day

Wednesday, June 9, 2021 - 9:30pm

Vapotherm, Inc. (NYSE: VAPO) is a publicly traded developer and manufacturer of advanced respiratory technology based in Exeter, New Hampshire, USA.

Key Points: 
  • Vapotherm, Inc. (NYSE: VAPO) is a publicly traded developer and manufacturer of advanced respiratory technology based in Exeter, New Hampshire, USA.
  • Over 2.8 million patients have been treated with the use of Vapotherm high velocity therapy systems.
  • Vapotherm high velocity therapy is mask-free noninvasive ventilatory support and is a front-line tool for relieving respiratory distressincluding hypercapnia, hypoxemia, and dyspnea.
  • Vapotherm routinely posts important information for investors on the Investor Relations section of its website, http://investors.vapotherm.com/ .

ERT Announces Real-Time Coaching for Pulmonary Function Tests Performed in the Patient's Home

Tuesday, June 8, 2021 - 1:00pm

PHILADELPHIA, June 8, 2021 /PRNewswire/ -- ERT , the global leader in data collection for clinical endpoints, today announced the launch of ERT iSpiro Virtual Visits, which enables real-time coaching during at-home pulmonary function tests (PFT).

Key Points: 
  • PHILADELPHIA, June 8, 2021 /PRNewswire/ -- ERT , the global leader in data collection for clinical endpoints, today announced the launch of ERT iSpiro Virtual Visits, which enables real-time coaching during at-home pulmonary function tests (PFT).
  • With iSpiro Virtual Visits, ERT delivers on its commitment to provide customer and patient-oriented innovations that facilitate decentralization.
  • "Performing spirometry correctly can be critical to the success of a drug approval," said Achim Schlke, Executive Vice President of ERT Respiratory Solutions.
  • By identifying trial risks before they become problems, ERT enables customers to bring clinical treatments to patients quickly and with confidence.

Worldwide Commercial Aircraft Oxygen System Industry to 2025 - Key Drivers, Challenges and Trends - ResearchAndMarkets.com

Friday, June 4, 2021 - 5:22pm

The "Global Commercial Aircraft Oxygen System Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Commercial Aircraft Oxygen System Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.
  • The publisher has been monitoring the commercial aircraft oxygen system market and it is poised to grow by $ 1.40 bn during 2021-2025 progressing at a CAGR of 12% during the forecast period.
  • The report on commercial aircraft oxygen system market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
  • The commercial aircraft oxygen system market analysis includes type segment, component segment and geographical landscapes.

The Worldwide Medical Oxygen Concentrators & Oxygen Cylinders Industry is Expected to Reach $4.62 Billion by 2028 - ResearchAndMarkets.com

Friday, June 4, 2021 - 4:22pm

The "Medical Oxygen Concentrators & Oxygen Cylinders Market Share, Size, Trends, Industry Analysis Report, By Product; By Technology; By End-users; By Regions; Segment Forecast, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Medical Oxygen Concentrators & Oxygen Cylinders Market Share, Size, Trends, Industry Analysis Report, By Product; By Technology; By End-users; By Regions; Segment Forecast, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.
  • The global medical oxygen concentrators & oxygen cylinders market size is expected to reach USD 4.62 billion by 2028 according to a new study.
  • Medical concentrators and cylinders are medical oxygen systems that are used to treat respiratory ailments and are commonly preferred by older patients who have limited mobility and rely on a consistent market supply.
  • The increasing market demand for medical concentrators and cylinders has resulted in the introduction and approval of new products in the market.

Expressing Gratitude to Respiratory Therapy Professionals

Friday, June 4, 2021 - 2:37pm

Since the days of 1918 Flu, through pulmonary tuberculosis, SARS and H1N1, and even Katrina, respiratory therapy has been there for them all.

Key Points: 
  • Since the days of 1918 Flu, through pulmonary tuberculosis, SARS and H1N1, and even Katrina, respiratory therapy has been there for them all.
  • Because of this, the American Association for Respiratory Care (AARC) developed a PSA video to highlight the profession and the work respiratory therapists do each day.
  • It also serves as a call to express our gratitude to these health care professionals, asking our community to take time to thank a respiratory therapist.
  • Like many health care professionals working on the front lines of the pandemic, respiratory therapists worked tirelessly and selflessly to help patients everywhere.

4D pharma Completes Enrollment of Part A of the Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma and Provides Program Update

Friday, June 4, 2021 - 12:00pm

Following the completion of enrollment of Part A, 4D pharma expects to announce topline results from these patients in the second half of 2021.

Key Points: 
  • Following the completion of enrollment of Part A, 4D pharma expects to announce topline results from these patients in the second half of 2021.
  • 4D pharma has demonstrated MRx-4DP0004s ability to reduce airway inflammation in a pre-clinical model of severe asthma.
  • The completion of enrollment in Part A of 4D pharmas asthma study is an important milestone for this program.
  • The first-in-human Phase I/II trial is a two part, multi-center, randomized, double-blind, placebo-controlled trial of MRx-4DP0004 in patients taking long-term medication for asthma.